EIP Pharma is a clinical stage therapeutics company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process.
We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a disease-modifying treatment for neurodegenerative diseases. Our lead indication is dementia with Lewy Bodies and neflamapimod has also been evaluated in early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke.
We have assembled a highly experienced executive management team led by our two co-founders, board of directors and scientific advisory board to execute on our mission to develop and commercialize innovative drug treatments for dementia with Lewy bodies, Alzheimer’s disease and other central nervous system disorders. Our management team is led by our Co-Founders, John Alam, MD and Sylvie Grégoire, PharmD.
EIP Pharma in the News
Presentation at 14th CTAD Conference November 10, 2021
November 10, 2021
EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment
November 4, 2021